The 340B program was created in late 1992 as a vehicle for increasing the availability of pharmaceuticals to indigent patients. Under the program, eligible hospitals can acquire pharmaceuticals for distribution to vulnerable patient populations at lower prices.
SHNPA insists that the 340B program has created opportunities for care for indigent patients nationwide and that the program is being used in the way that it was intended. The group cites independent research showing 340B’s benefits as well as money savings calculations on local, state and federal levels.
The organization says that it is willing to work with both supporters and critics of 340B and supports program reforms, including pricing transparency, audits of drug manufacturers and investigation of the use of contract pharmacies to meet 340B program goals.
The report directly counters a white paper released by a collection of pharmaceutical and biotechnology associations earlier this year.
More Articles on News:
10 States Prepare for Health Record Exchange Following Diasasters
All 25 Resolute Anesthesia and Pain Solutions Practices Adopt Anesthesia Cloud
Healthcare Reform Demands Innovative Thinking from Hospital Leaders
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.